Susmed (TSE:4263) Loans Receivable: 円0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
60 GF Score
Price 円569.00
GF Value 円904.67
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Susmed Loans Receivable?

Susmed TSE:4263 -1.22% 60 Loans Receivable is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:4263 with a GF Score™ of 60/100 and a GF Value™ of 円904.67 (Possible Value Trap). The stock has 4 warning signs investors should review.

Susmed's Loans Receivable for the quarter that ended in Mar. 2026 was 円0.0 Mil.

Susmed Loans Receivable Historical Data

* Premium members only.

The historical data trend for Susmed's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed Loans Receivable Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Susmed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4263
60GF Score
Susmed Inc TSE:4263
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Susmed Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of 円0.0 Mil mean?
Susmed (TSE:4263) has a Loans Receivable of 円0.0 Mil as of Mar. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Susmed and its competitors.
Is Susmed's Loans Receivable too high?
Susmed's current Loans Receivable is 円0.0 Mil. Overall, Susmed has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Susmed's Loans Receivable compare to VEEV and BTSG?
Susmed's Loans Receivable of 円0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Healthcare Providers & Services company?
A good Loans Receivable depends on the Healthcare Providers & Services industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Susmed and its competitors. Susmed's current Loans Receivable is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Possible Value Trap. The stock's GF Value™ is 円904.67, compared to a current price of 円569.00 — trading 37.1% below its estimated fair value. The current Loans Receivable is 円0.0 Mil. Susmed's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Susmed (TSE:4263), the current Loans Receivable is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円569.00 is trading 37.1% below its estimated GF Value™ of 円904.67. GuruFocus considers Susmed to be Possible Value Trap.

Key valuation signals for TSE:4263:

  • Loans Receivable: 円0.0 Mil
  • GF Value™: 円904.67 vs. price of 円569.00 (37.1% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
60GF Score

Get the complete analysis for TSE:4263

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円569.00
Price
円904.67
GF Value